Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- PMID: 34246358
- PMCID: PMC8266301
- DOI: 10.1016/S0140-6736(21)01429-X
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
Erratum in
-
Department of Error.Lancet. 2022 Jan 29;399(10323):436. doi: 10.1016/S0140-6736(21)02787-2. Lancet. 2022. PMID: 35093230 Free PMC article. No abstract available.
Abstract
Background: CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.
Methods: This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 μg inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 0·5 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting.
Findings: Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 [65·1%] in the vaccine group and 3568 [34·9%] in the placebo group) and the per protocol group consisted of 10 029 participants (6559 [65·4%] and 3470 [34·6%]) who received two doses of vaccine or placebo. During a median follow-up period of 43 days (IQR 36-48), nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group (31·7 cases [14·6-59·3] per 1000 person-years) and 32 cases were reported in the placebo group (192·3 cases [135·7-261·1] per 1000 person-years) 14 days or more after the second dose, yielding a vaccine efficacy of 83·5% (95% CI 65·4-92·1; p<0·0001). The frequencies of any adverse events were 1259 (18·9%) in the vaccine group and 603 (16·9%) in the placebo group (p=0·0108) with no fatalities or grade 4 adverse events. The most common systemic adverse event was fatigue (546 [8·2%] participants in the vaccine group and 248 [7·0%] the placebo group, p=0·0228). Injection-site pain was the most frequent local adverse event (157 [2·4%] in the vaccine group and 40 [1·1%] in the placebo group, p<0·0001).
Interpretation: CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile.
Funding: Turkish Health Institutes Association.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests We declare no competing interests.
Figures
Comment in
-
One Health or Planetary Health for pandemic prevention? - Authors' reply.Lancet. 2020 Dec 12;396(10266):1882-1883. doi: 10.1016/S0140-6736(20)32392-8. Lancet. 2020. PMID: 33308466 No abstract available.
-
CoronaVac: more data for regulators and policy makers.Lancet. 2021 Jul 17;398(10296):186-188. doi: 10.1016/S0140-6736(21)01543-9. Epub 2021 Jul 8. Lancet. 2021. PMID: 34246359 Free PMC article. No abstract available.
-
CoronaVac efficacy data from Turkey.Lancet. 2021 Nov 20;398(10314):1873-1874. doi: 10.1016/S0140-6736(21)02288-1. Lancet. 2021. PMID: 34801104 Free PMC article. No abstract available.
Similar articles
-
The immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy individuals: A systematic review and meta-analysis.Transpl Immunol. 2022 Dec;75:101732. doi: 10.1016/j.trim.2022.101732. Epub 2022 Oct 31. Transpl Immunol. 2022. PMID: 36328249 Free PMC article. Review.
-
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2.Hum Vaccin Immunother. 2022 Nov 30;18(6):2096970. doi: 10.1080/21645515.2022.2096970. Epub 2022 Jul 25. Hum Vaccin Immunother. 2022. PMID: 35878789 Free PMC article. Review.
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3. Lancet Infect Dis. 2021. PMID: 33548194 Free PMC article. Clinical Trial.
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217362 Free PMC article. Clinical Trial.
Cited by
-
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review.Vaccines (Basel). 2024 May 18;12(5):554. doi: 10.3390/vaccines12050554. Vaccines (Basel). 2024. PMID: 38793805 Free PMC article. Review.
-
Frequency of Developing COVID-19 Pneumonia in Patients Who Were Vaccinated Double-Dose CoronaVac: Data of the Pandemic Authorized Hospital in Northern Cyprus.Ethiop J Health Sci. 2023 Sep;33(5):725-734. doi: 10.4314/ejhs.v33i5.2. Ethiop J Health Sci. 2023. PMID: 38784514 Free PMC article.
-
Poor immune response to inactivated COVID-19 vaccine in patients with hypertension.Front Med (Lausanne). 2024 May 2;11:1329607. doi: 10.3389/fmed.2024.1329607. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38756945 Free PMC article.
-
Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly.Curr Microbiol. 2024 May 13;81(7):171. doi: 10.1007/s00284-024-03689-7. Curr Microbiol. 2024. PMID: 38739274
-
Effects of Repeated Doses of the Vero Cell Vaccine (SARS-Cov-2 Inactivated Vaccine) on Renal Functions in Balb/C Albino Mice.J Inflamm Res. 2024 May 8;17:2851-2860. doi: 10.2147/JIR.S455682. eCollection 2024. J Inflamm Res. 2024. PMID: 38737106 Free PMC article.
References
-
- Kniffin KM, Narayanan J, Anseel F, et al. COVID-19 and the workplace: implications, issues, and insights for future research and action. Am Psychol. 2021;76:63–77. - PubMed
-
- WHO Health inequity and the effects of COVID-19: assessing, responding to and mitigating the socioeconomic impact on health to build a better future. 2020. https://apps.who.int/iris/handle/10665/338199
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous